Ampio To Test Inhaled COVID-19 Treatment In India

by Vandana Singh, Benzinga Editor

September 21, 2021 3:46 PM | 1 min read | Make a Comment

The Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) has approved Phase 2 COVID-19 trial of Ampio Pharmaceuticals Inc's AMPE Ampion.
The study will utilize inhaled Ampion to treat those suffering from respiratory distress due to COVID-19.
Related Link: Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality.
The AP-019 treatment protocol was approved with no recommended changes.
Related: Ampio's US Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway.
Price Action: AMPE stock is up 5.34% at $1.73 during the market session on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care Small Cap Movers Trading Ideas General Briefs COVID-19 Coronavirus Phase 2 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.